Perimenopause — the years leading up to menopause, typically beginning in a woman's mid-40s but sometimes as early as the late 30s — is when many women notice a sudden acceleration in facial aging. It is not your imagination. The hormonal shifts of perimenopause drive measurable, structural changes in skin collagen, thickness, hydration, and elasticity that progress faster than chronological aging alone.
This article explains what is happening to the skin during perimenopause, which changes are driven by estrogen decline versus normal aging, what the evidence supports for treatment, and how to sequence interventions from least to most invasive.
Why perimenopause changes the face
Estrogen is not only a reproductive hormone. The skin is an endocrine organ with estrogen receptors distributed throughout the epidermis, dermis, and subcutaneous tissue. Estrogen directly influences:
- Collagen synthesis — estrogen stimulates fibroblasts to produce type I and type III collagen
- Elastin maintenance — estrogen preserves elastic fiber structure
- Hyaluronic acid production — estrogen supports glycosaminoglycan synthesis, which retains water
- Sebum production — estrogen modulates oil gland activity
- Wound healing — estrogen accelerates tissue repair and reduces inflammation
- Skin thickness — estrogen maintains epidermal and dermal thickness
When estrogen begins to fluctuate and decline during perimenopause, all of these functions are affected. The result is not just dryness — it is a fundamental restructuring of the skin's support architecture.
The 30% collagen statistic
The most frequently cited data point in menopause dermatology: women lose approximately 30% of their skin collagen in the first five years after menopause, with a continued decline of about 2% per year thereafter.
This figure comes from multiple published studies and is cited in a 2026 roundtable discussion published in the Journal of Cosmetic Dermatology (PMC12747467), where a panel of two dermatologists, a gynecologist, and a facial plastic surgeon provided consensus recommendations on treating perimenopausal and menopausal skin. The same statistic appears in a 2025 narrative review in the Journal of Cosmetic Dermatology and in Galderma's 2026 global survey presented at IMCAS.
The collagen loss begins before menopause itself. Collagen production starts declining around age 25 at approximately 1% per year. By the time perimenopause begins — typically 8–10 years before menopause — the cumulative loss already makes the skin more vulnerable to the abrupt hormonal drop.
What changes — and when
During perimenopause (typically ages 38–50)
Estrogen levels fluctuate rather than decline smoothly. This variability produces inconsistent signals to skin fibroblasts. Patients may notice:
- Increased dryness — hyaluronic acid levels drop, reducing the skin's ability to retain moisture
- New or worsening sensitivity — the skin barrier becomes less robust
- Uneven pigmentation — estrogen influences melanocyte activity; fluctuations trigger patchy hyperpigmentation
- Slower healing — post-inflammatory marks from acne, irritation, or minor injuries last longer
- Adult acne — the ratio of androgens to estrogen shifts, increasing oil production in some women
- Early volume loss — subtle hollowing under the eyes and in the midface
At menopause and beyond (average age 51)
When periods have stopped for 12 consecutive months, estrogen reaches consistently low levels. The accelerated changes become more visible:
- Thinning skin — skin thickness decreases by approximately 1.13% per postmenopausal year
- Loss of firmness — elastin degradation outpaces replacement
- Deepening wrinkles — collagen scaffold weakening allows lines to etch more deeply
- Bone resorption — the facial skeleton itself changes, with loss of maxillary and mandibular bone volume altering facial proportions
- Increased bruising — thinner skin and fragile capillaries
What the evidence supports for treatment
A 2025 narrative review in the Journal of Cosmetic Dermatology, titled "Managing Menopausal Skin Changes," categorized available treatments by evidence level. A 2026 roundtable in the same journal expanded on these with clinical consensus. The following framework is based on those sources and the AAD's guidance on menopause skin care.
Tier 1: Foundation (every perimenopausal patient)
These are non-negotiable regardless of whether you pursue in-office treatments:
Sunscreen. Broad-spectrum SPF 30 or higher, applied daily. UV damage compounds estrogen-driven collagen loss. Sun protection does not reverse aging but prevents acceleration.
Topical retinoids. Tretinoin (prescription) or retinol/retinaldehyde (over-the-counter) are the gold standard for stimulating collagen production, improving epidermal thickness, and increasing cell turnover. The 2026 roundtable identified retinoids as a foundational treatment for menopausal skin. Caveat: perimenopausal skin is often more sensitive, so start at low concentrations and increase gradually.
Barrier repair moisturizers. Ceramide-based, fragrance-free formulations help restore the compromised skin barrier. Hyaluronic acid serums provide temporary plumping but do not replace the structural role of collagen.
Gentle cleansing. Avoid harsh surfactants that strip the already-weakened lipid barrier.
Tier 2: In-office treatments (evidence-supported)
CO2 laser resurfacing. The 2026 roundtable panel identified CO2 laser as one of the most effective interventions for hormone-related skin changes. It triggers controlled dermal injury that stimulates new collagen production. Fractional CO2 is preferred over fully ablative for perimenopausal patients because healing is faster and the risk of PIH is lower. Recovery takes 7–14 days, with collagen remodeling continuing for 3–6 months.
Biostimulators (poly-L-lactic acid, e.g., Sculptra). These injectables work by stimulating the body's own collagen production over weeks to months. The roundtable experts specifically recommended injectable poly-L-lactic acid as one of the most effective interventions for hormone-related volume loss. Results develop gradually and can last 2+ years. Galderma's 2026 IMCAS presentation highlighted biostimulators as a key treatment for menopausal skin, noting that Sculptra "boosts elastin and collagen across the three layers of the skin."
Hyaluronic acid fillers. Address immediate volume loss in cheeks, temples, and under-eyes. They do not stimulate collagen but restore contour that collagen loss has diminished. Fillers and biostimulators are often combined — fillers for immediate correction, biostimulators for longer-term structural improvement.
Skin-tightening devices. Microfocused ultrasound (e.g., Ultherapy) and radiofrequency devices address laxity by delivering energy to the dermis to trigger collagen contraction and new deposition. The roundtable noted the broad range of energy-based options available, including lasers, radiofrequency, microfocused ultrasound, and IPL.
RF microneedling. Devices like Morpheus8 and Sylfirm X combine mechanical microneedling with radiofrequency energy to remodel collagen at controlled depths. Effective for texture, laxity, and early volume changes. A facial plastic surgeon quoted in a 2026 Substack article on menopause and aesthetics specifically recommended RF microneedling alongside biostimulators and fat grafting for restoring volume and enhancing collagen production.
Tier 3: Hormone-related interventions (requires medical supervision)
Hormone replacement therapy (HRT). Systemic HRT restores estrogen levels and has been shown to partially reverse collagen loss, increase dermal thickness, and improve elasticity. A review in the Journal of Integrative Dermatology (2025) noted that 17β-estradiol treatment increased both type I and type III collagen in postmenopausal skin. However, HRT is not recommended solely for cosmetic purposes due to its systemic risk profile. Decisions about HRT should be made with a gynecologist or endocrinologist based on the full clinical picture.
Topical estrogen. Topical estriol (a gentler form of estrogen) applied to the face has shown improvements in skin elasticity, firmness, and wrinkle depth in small clinical studies. The evidence is emerging but promising, and the systemic absorption is minimal when used appropriately.
Tier 4: Emerging and less-established options
- Exosomes: Proposed to modulate cellular signaling and regeneration. Preclinical data suggest potential, but the 2025 review classified exosomes as "largely experimental" with a lack of standardized products, long-term safety data, and robust clinical evidence.
- PRP/PRF: Platelet-rich plasma and platelet-rich fibrin deliver growth factors that may support collagen production. Evidence is mixed and highly technique-dependent.
- PDRN and polynucleotides: DNA fragments proposed to stimulate tissue repair. Early clinical data exist but the evidence base is thinner than for established treatments.
How to sequence treatments
There is no single correct order, but a rational sequencing considers invasiveness, recovery, and whether treatments complement each other:
- Start with foundation skincare (sunscreen, retinoids, barrier repair) — this should begin immediately and continue indefinitely.
- Address volume loss — biostimulators or fillers restore the structural support that collagen loss has diminished. Biostimulators are increasingly recommended as the first injectable choice for perimenopausal patients because they work with the body's own collagen production rather than simply filling.
- Address skin quality and texture — fractional CO2 laser or RF microneedling for collagen remodeling, pigment correction, and texture improvement.
- Address laxity — skin-tightening devices (Ultherapy, Sofwave, or RF devices) if laxity persists after collagen stimulation from biostimulators and resurfacing.
- Address surgical concerns last — for patients with significant laxity or structural changes that energy-based devices cannot adequately address, surgical consultation is appropriate. Perimenopause is often the time when patients first consider whether a surgical approach is warranted.
The key principle: treat the underlying structural decline before chasing surface-level fixes. A hyaluronic acid filler that restores cheek volume will look better and last longer on skin that has been prepared with collagen-stimulating treatments and proper skincare.
What to discuss with your provider
- Your menstrual history and where you are in the perimenopause transition — this influences treatment intensity and skin tolerance
- Whether you are on HRT or considering it — this affects treatment planning
- Your skin type (Fitzpatrick classification) — darker skin types require modified laser settings to avoid PIH
- Your tolerance for downtime — this determines which devices and depths are appropriate
- Your budget over 12–24 months — collagen-stimulating treatments are staged, not one-time events
- Whether your provider has experience with perimenopausal and menopausal skin specifically — the hormonal context changes treatment selection
Sources
- Fabi SG, Firsowicz M, Kamrani P, Draelos ZD, Dayan SH. Round table discussion: aesthetic treatment considerations for the perimenopausal and menopausal patient. J Cosmet Dermatol. 2026;25(1):e70626. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12747467
- Viscomi B, Muniz M, Sattler S. Managing menopausal skin changes: a narrative review. J Cosmet Dermatol. 2025;24(Suppl 4):e70393. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12374573
- Galderma. Galderma tackles menopause-related skin changes with global survey and clinical trial inclusivity. January 30, 2026. Available at: https://www.galderma.com/news/galderma-tackles-menopause-related-skin-changes
- American Academy of Dermatology. Caring for your skin in menopause. Available at: https://www.aad.org/public/everyday-care/skin-care-secrets/anti-aging/skin-care-during-menopause
- Azizzadeh B. From serums to facelifts: navigating the aging journey during menopause. The Modern Face (Substack). 2026. Available at: https://drazizzadeh.substack.com/p/from-serums-to-facelifts-navigating
